0001192482-18-000037.txt : 20180112 0001192482-18-000037.hdr.sgml : 20180112 20180112161550 ACCESSION NUMBER: 0001192482-18-000037 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180110 FILED AS OF DATE: 20180112 DATE AS OF CHANGE: 20180112 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Fleming Alison B CENTRAL INDEX KEY: 0001640701 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37372 FILM NUMBER: 18526151 MAIL ADDRESS: STREET 1: 780 DEDHAM STREET, SUITE 800 CITY: CANTON STATE: MA ZIP: 02021 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: COLLEGIUM PHARMACEUTICAL, INC CENTRAL INDEX KEY: 0001267565 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: VA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 780 DEDHAM STREET, SUITE 800 CITY: CANTON STATE: MA ZIP: 02021 BUSINESS PHONE: 781-713-3699 MAIL ADDRESS: STREET 1: 780 DEDHAM STREET, SUITE 800 CITY: CANTON STATE: MA ZIP: 02021 FORMER COMPANY: FORMER CONFORMED NAME: COLLEGIUM PHARMACEUTICAL INC DATE OF NAME CHANGE: 20031020 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2018-01-10 0001267565 COLLEGIUM PHARMACEUTICAL, INC COLL 0001640701 Fleming Alison B C/O COLLEGIUM PHARMACEUTICAL, INC. 780 DEDHAM STREET, SUITE 800 CANTON MA 02021 0 1 0 0 Chief Technology Officer Common Stock 2018-01-10 4 M 0 6928 .48 A 32651 D Common Stock 2018-01-10 4 S 0 6928 19.07 D 25723 D Stock option (right to purchase) .48 2018-01-10 4 M 0 6928 0 D 2023-01-24 Common Stock 6928 5753 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2017. The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.00 to $19.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. All of the options were fully vested and exercisable as of January 10, 2018. /s/ Paul Brannelly as Attorney-In-Fact For Alison B. Fleming 2018-01-12